SpliceHetero: An information theoretic approach for measuring spliceomic intratumor heterogeneity from bulk tumor RNA-seq

Autoři: Minsu Kim aff002;  Sangseon Lee aff002;  Sangsoo Lim aff001;  Sun Kim aff001
Působiště autorů: Department of Computer Science and Engineering, Seoul National University, Seoul, 08826, Korea aff001;  Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, 08826, Korea aff002;  Bioinformatics Institute, Seoul National University, Seoul, 08826, Korea aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223520



Intratumor heterogeneity (ITH) represents the diversity of cell populations that make up cancer tissue. The level of ITH in a tumor is usually measured by a genomic variation profile, such as copy number variation and somatic mutation. However, a recent study has identified ITH at the transcriptome level and suggested that ITH at gene expression levels is useful for predicting prognosis. Measuring ITH levels at the spliceome level is a natural extension. There are serious technical challenges in measuring spliceomic ITH (sITH) from bulk tumor RNA sequencing (RNA-seq) due to the complex splicing patterns.


We propose an information-theoretic method to measure the sITH of bulk tumors to overcome the above challenges. This method has been extensively tested in experiments using synthetic data, xenograft tumor data, and TCGA pan-cancer data. As a result, we showed that sITH is closely related to cancer progression and clonal heterogeneity, along with clinically significant features such as cancer stage, survival outcome and PAM50 subtype. As far as we know, it is the first study to define ITH at the spliceome level. This method can greatly improve the understanding of cancer spliceome and has great potential as a diagnostic and prognostic tool.

Klíčová slova:

Breast cancer – Cancer genomics – Evolutionary genetics – Introns – RNA sequencing – Somatic mutation – Transcriptome analysis – RNA alignment


1. Boland CR, Goel A. Somatic evolution of cancer cells. In: Seminars in cancer biology. vol. 15. Elsevier; 2005. p. 436–450.

2. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28.

3. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2010;1805(1):105–117. doi: 10.1016/j.bbcan.2009.11.002

4. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306. doi: 10.1038/nature10762 22258609

5. Sun Xx, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica. 2015;36(10):1219. doi: 10.1038/aps.2015.92 26388155

6. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi: 10.1016/j.cell.2017.01.018 28187284

7. Venet D, Pecasse F, Maenhaut C, Bersini H. Separation of samples into their constituents using gene expression data. Bioinformatics. 2001;17(suppl_1):S279–S287. doi: 10.1093/bioinformatics/17.suppl_1.s279 11473019

8. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. The Journal of clinical investigation. 2010;120(2):636–644. doi: 10.1172/JCI40724 20101094

9. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methylation variation in epigenetic domains across cancer types. Nature genetics. 2011;43(8):768. doi: 10.1038/ng.865 21706001

10. Morris LG, Riaz N, Desrichard A, Şenbabaoğlu Y, Hakimi AA, Makarov V, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016;7(9):10051. doi: 10.18632/oncotarget.7067 26840267

11. Yang F, Wang Y, Li Q, Cao L, Sun Z, Jin J, et al. Intratumor heterogeneity predicts metastasis of triple-negative breast cancer. Carcinogenesis. 2017;38(9):900–909. doi: 10.1093/carcin/bgx071 28911002

12. Oh BY, Shin HT, Yun JW, Kim KT, Kim J, Bae JS, et al. Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. Scientific reports. 2019;9(1):4542. doi: 10.1038/s41598-019-41098-0 30872730

13. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nature biotechnology. 2012;30(5):413. doi: 10.1038/nbt.2203 22544022

14. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nature methods. 2014;11(4):396. doi: 10.1038/nmeth.2883 24633410

15. Park Y, Lim S, Nam JW, Kim S. Measuring intratumor heterogeneity by network entropy using RNA-seq data. Scientific reports. 2016;6:37767. doi: 10.1038/srep37767 27883053

16. Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heterogeneity of the epigenome. Cancer cell. 2016;29(4):440–451. doi: 10.1016/j.ccell.2016.03.009 27070699

17. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic acids research. 2016;45(D1):D353–D361. doi: 10.1093/nar/gkw1092 27899662

18. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes & development. 2010;24(21):2343–2364. doi: 10.1101/gad.1973010

19. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. OncoTargets and therapy. 2014;7:57.

20. Paronetto MP, Passacantilli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell death and differentiation. 2016;23(12):1919. doi: 10.1038/cdd.2016.91 27689872

21. Read A, Natrajan R. Splicing dysregulation as a driver of breast cancer. Endocrine-related cancer. 2018;25(9):R467–R478. doi: 10.1530/ERC-18-0068 29848666

22. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer cell. 2018;34(2):211–224. doi: 10.1016/j.ccell.2018.07.001 30078747

23. Sveen A, Kilpinen S, Ruusulehto A, Lothe R, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35(19):2413. doi: 10.1038/onc.2015.318 26300000

24. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nature Reviews Urology. 2009;6(8):454. doi: 10.1038/nrurol.2009.125 19657379

25. Wan Y, Larson DR. Splicing heterogeneity: separating signal from noise. Genome biology. 2018;19(1):86. doi: 10.1186/s13059-018-1467-4 29986741

26. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013;498(7453):236. doi: 10.1038/nature12172 23685454

27. Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome medicine. 2015;7(1):45. doi: 10.1186/s13073-015-0168-9 26113877

28. Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K, et al. RNA sequencing of cancer reveals novel splicing alterations. Scientific reports. 2013;3:1689. doi: 10.1038/srep01689 23604310

29. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, et al. Systematic analysis of splice-site-creating mutations in cancer. Cell reports. 2018;23(1):270–281. doi: 10.1016/j.celrep.2018.03.052 29617666

30. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–1401. doi: 10.1126/science.1254257 24925914

31. Ardui S, Ameur A, Vermeesch JR, Hestand MS. Single molecule real-time (SMRT) sequencing comes of age: applications and utilities for medical diagnostics. Nucleic acids research. 2018;46(5):2159–2168. doi: 10.1093/nar/gky066 29401301

32. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. doi: 10.1093/bioinformatics/bts635 23104886

33. Lin J. Divergence measures based on the Shannon entropy. IEEE Transactions on Information theory. 1991;37(1):145–151. doi: 10.1109/18.61115

34. Joyce JM. Kullback-leibler divergence. In: International Encyclopedia of Statistical Science. Springer; 2011. p. 720–722.

35. Capra JA, Singh M. Predicting functionally important residues from sequence conservation. Bioinformatics. 2007;23(15):1875–1882. doi: 10.1093/bioinformatics/btm270 17519246

36. Azad RK, Li J. Interpreting genomic data via entropic dissection. Nucleic acids research. 2012;41(1):e23–e23. doi: 10.1093/nar/gks917 23036836

37. O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic acids research. 2015;44(D1):D733–D745. doi: 10.1093/nar/gkv1189 26553804

38. MIT. WgSim; 2011. Available from: https://github.com/lh3/wgsim.

39. Graf JF, Zavodszky MI. Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures. PloS one. 2017;12(11):e0188878. doi: 10.1371/journal.pone.0188878 29190747

40. Network CGA, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61. doi: 10.1038/nature11412

41. Zhu D, Zhaozu X, Cui G, Chang S, See YX, Lim MGL, et al. Single-cell transcriptome analysis reveals estrogen signaling augments the mitochondrial folate pathway to coordinately fuel purine and polyamine synthesis in breast cancer cells. bioRxiv. 2018; p. 246363.

42. Chen H, Lin F, Xing K, He X. The reverse evolution from multicellularity to unicellularity during carcinogenesis. Nature communications. 2015;6:6367. doi: 10.1038/ncomms7367 25751731

43. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nature genetics. 2013;45(10):1113. doi: 10.1038/ng.2764 24071849

44. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology. 2009;27(8):1160. doi: 10.1200/JCO.2008.18.1370 19204204

Článek vyšel v časopise


2019 Číslo 10